Navigation Links
Biocept and Academic Collaborators to Present Poster at ASCO on Circulating Tumor Cells (CTCs)
Date:6/2/2011

SAN DIEGO, June 2, 2011 /PRNewswire/ -- Biocept, Inc. today reported that its scientists and academic collaborators will present a poster at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, Illinois June 3-7. The poster presentation is based on studies performed utilizing Biocept's proprietary OncoCEE™ (Oncology Cell Enrichment and Extraction) technology platform for the capture, detection, enumeration and analysis of circulating tumor cells (CTCs).  OncoCEE™ enables not only CTC enumeration but also biomarker analysis, such as fluorescent in situ hybridization (FISH) performed on the CTCs, as demonstrated in this study of HER2 (Human Epidermal growth factor Receptor-2) analysis in 54 patients diagnosed with late stage metastatic/recurrent breast cancer.

Farideh Bischoff, PhD, Vice President, Translational Research at Biocept, said, "The data we are presenting not only addresses our ability to capture CTCs in patient samples using a cocktail of antibodies, but also to perform FISH for HER2 gene amplification on the intact CTCs.  Further, we show that CTCs are heterogeneous, like the tumors that shed them, and are potentially comprised of different populations.  For example, while concordance was generally very high between HER2 results on tumor tissue and CTCs, certain patients that are HER2+ by tissue evaluation could have HER2+ or HER2- CTCs, and even in those that had HER2+ CTCs, typically all were not positive.  The opposite was also true – certain HER2- patients by tissue analysis were shown to have HER2+ CTCs.  We think these results could have important clinical implications for patients."

A second presentation, published as an abstract, involved collaborators from MD Anderson and USC, and focused on CTCs in ovarian and colorectal cancer.  Key findings were that CTCs lacking cytokeratin (CK), an important CTC marker, could be identified through aneuploidy, and that these CK- cells, while fewer in number than CK+ CTCs, appeared to correlate better with clinical outcome.

Additional details for the ASCO posters or abstract are as follows:

Mon, June 6, 8:00 AM - 12:00 PM: Hall A, poster #35H

Abstract #10631 - Redefining CTCs: Detection of additional circulating tumor cells using an antibody capture cocktail and HER2 FISH

F. Z. Bischoff, T. J. Pircher, T. Pham, K. Wong, S. Mikolajczyk, P. Cotter, J. A. Mayer; Biocept Inc., San Diego, CA

Clinical Relevance of cytokeratin negative circulating tumor cells

C. V. Pecot, F. Z. Bischoff, Y. G. Lin, P. Jaladurgam, W. M. Merritt, T. J. Pircher, S. Mikolajczyk, J. A. Mayer, K. Wong, T. Pham, J. N. Bottsford-Miller, R. L. Stone, J. Celestino, A. M. Nick, C. Eng, A. Sood; University of Texas M. D. Anderson Cancer Center, Houston, TX; Biocept Inc., San Diego, CA; University of Southern California, Los Angeles, CA

About Biocept, Inc.

Biocept Laboratories, headquartered in San Diego, California, is an advanced CLIA-certifed laboratory services company specializing in the capture, detection, enumeration and analysis of Circulating Tumor Cells (CTCs).  Biocept's mission is to enhance the lives of cancer patients through the development of innovative diagnostic products and services.   Biocept utilizes innovative, proprietary technologies to deliver clinically relevant and actionable information to physicians that enable better patient care.  This includes clinical assessments of CTCs, both prognostic and predictive, which may provide physicians with important information for the treatment of their patients with cancer.

About OncoCEE™

The OncoCEE™ platform, developed by Biocept, has demonstrated that it can consistently and accurately capture extremely rare cells, like CTCs, which may be present in only 1 of every 50-100 billion blood cells.  Biocept obtains patient samples via a simple blood draw, or "liquid biopsy", instead on relying on traditional biopsy methods or surgical procedures.  Existing methods to detect and enumerate CTCs rely only on the expression of epithelial cell adhesion molecule (EpCAM) and cytokeratins.  This limited selection may exclude cells that have undergone intrinsic modifications of their phenotype such as epithelial/mesenchymal transition (EMT).   EMT may represent a possible explanation for patients who, despite an aggressive disease, are found negative for the presence of CTCs.  Because it employs an antibody cocktail, OncoCEE™ has the potential to capture not only EpCAM but also mesenchymal-like cells.  Additionally, OncoCEE™ enables in situ analysis of predictive biomarkers like HER2 estrogen receptor (ER) and progesterone receptor (PR).

For more information, please contact Michael Dunn, Sr VP of Corporate Development at 888-332-7729 or by visiting Biocept's web site at http://www.biocept.com . The Company's website is not part of this press release.


'/>"/>
SOURCE Biocept, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biocept Announces Study to Isolate Circulating Tumor Cells from Blood
2. Biocept, Inc. Announces Issuance of Patent for its Microfluidic Technology
3. Biocept and Academic Collaborators to Present Posters at AACR on Circulating Tumor Cells (CTCs)
4. Lyle Arnold, PhD and Michael Dunn Join Biocept Management Team
5. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
6. Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
7. Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting
8. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
9. Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R)
10. Bioniche Pharma and Academic Pharmaceuticals, Inc. Announce the Introduction of Sotalol Hydrochloride Injection
11. MedImmune to Present Five Abstracts on RSV at Pediatric Academic Societies Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , February 5, 2016 ... Market Research report states that the global active pharmaceuticals ... and is predicted to reach US$185.9 bn by 2020. ... 6.50% from 2014 to 2020. The title of the ... Captive/Contract Manufactured, by Geography, and by Therapeutic Area) - ...
(Date:2/5/2016)... India , February 5, 2016 ... a new market research report "Fetal (Labor & Delivery) ... & Antepartum), Warmer, Incubator, Pulse Oximeter, Phototherapy/Jaundice Management Devices, ... published by MarketsandMarkets, This report studies the global market ... market is estimated at USD 6.28 Billion in 2015 ...
(Date:2/5/2016)... February 4, 2016 France , ... , UK, and Israel ). It includes a ... and 3 GD, segmented by age and sex in these markets. GD ... EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis ... , Germany , Italy , ...
Breaking Medicine Technology:
(Date:2/6/2016)... Aliso Viejo, CA (PRWEB) , ... February 06, 2016 , ... ... can quickly and easily add warm color grades to their footage. A LUT is ... changes every pixel's color to the corresponding color indicated by the table. By manipulating ...
(Date:2/5/2016)... ... , ... Steven Tonkinson, 36, of Coconut Grove, Florida, ran the Miami Marathon ... 2003. This year, he ran all 26.2 miles with a green 25-pound ShelterBox strapped ... Heat. , This Sunday, while many are watching the Superbowl, Steven Tonkinson will strap ...
(Date:2/5/2016)... & Salt Lake City, UT (PRWEB) , ... February 05, 2016 ... ... of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi ... New Really Cool Humans Amateur TV Network. , Each week, on his weekly Whole-Food ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy Association ... restaurants, launched the 14th annual “Appetite for a Cure” campaign on Feb. 1 ... ALS and related diseases that severely limit strength and mobility. , Now ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... College President George H. Van Allen have signed a joint enrollment and degree ... a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , The ...
Breaking Medicine News(10 mins):